MEI Pharma, Inc. - MEIP STOCK NEWS

MEI Pharma, Inc. (NASDAQ: MEIP) has announced the grant of inducement stock options totaling 131,000 shares to four new employees as per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.39, equal to the closing stock price on the grant date. They are part of MEI's 2021 Inducement Grant Equity Compensation Plan and vest progressively over a decade. MEI Pharma focuses on advancing new cancer therapies, with its drug candidates currently in clinical trials aimed at marketing approval.

MEI Pharma, Inc. (Nasdaq: MEIP) announced the retirement of Dr. Christine A. White, who will not seek reelection as chair of the board after 12 years of service. Charles V. Baltic III has been elected as the new chair effective immediately after the fiscal year 2023 annual stockholders' meeting. Dr. White's contributions were commended by CEO Daniel P. Gold, highlighting her impact on the company's growth and oncology drug development. Mr. Baltic has a long history with MEI and brings extensive industry experience, which is expected to support the company's mission in advancing cancer therapies.

MEI Pharma reported fiscal year 2022 results with $153 million in cash and a net loss of $54.5 million, or $0.44 per share. The company marked milestones, including the first patient dosed in its Phase 3 COASTAL study and promising data for zandelisib in Phase 2 trials. However, regulatory challenges arose as the FDA modified its approach to accelerated approvals, impacting zandelisib's marketing pathway. Despite this, MEI remains committed to developing therapies for B-cell malignancies, with upcoming updates expected from various clinical studies.

MEI Pharma (NASDAQ: MEIP) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference 2022. The company will present a business update available for on-demand listening starting September 12, 2022, at 7:00 a.m. Eastern Time. The presentation will be accessible through the Investors section on the MEI Pharma website and archived for 90 days. MEI Pharma focuses on advancing cancer therapies, with candidates like zandelisib undergoing clinical trials for FDA marketing approvals.

MEI Pharma, Inc. (NASDAQ: MEIP) has granted inducement stock options totaling 64,000 shares to two new employees, aligning with Nasdaq Listing Rule 5635(c)(4). The options, priced at $0.51 per share, mirror the company's stock closing price on the grant date. These options are part of the 2021 Inducement Grant Equity Compensation Plan and are set to vest over time, beginning with 25% after one year, followed by monthly vesting for the next 36 months. MEI Pharma focuses on developing cancer therapies, including its clinical-stage candidate zandelisib.

MEI Pharma, Inc. (NASDAQ: MEIP) will announce its fiscal year-end 2022 financial results on September 8, 2022, after market close. A conference call will follow at 5:00 p.m. ET to provide a corporate overview and updates. Investors can join via a dial-in or access a live webcast through the company's website. MEI Pharma focuses on developing therapies for cancer, with ongoing clinical trials for zandelisib and other drug candidates aimed at addressing unmet medical needs. For further details, visit www.meipharma.com.

MEI Pharma, Inc. (NASDAQ: MEIP) has granted inducement stock options for 18,000 shares to a new employee, aligning with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.48 per share, matching the stock's closing price on the grant date. Vested shares will be released over a 40-month schedule, with a 10-year term. MEI Pharma is focused on developing cancer therapies, including zandelisib, which is in clinical trials aimed at securing FDA marketing approval.

MEI Pharma (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. have published Phase 1b clinical study results for zandelisib, a PI3Kδ inhibitor, in The Lancet Oncology. The study showed that an intermittent dosing schedule of zandelisib resulted in a lower risk of significant adverse events than a continuous regimen, without sacrificing efficacy. Out of 97 patients evaluated, the intermittent group exhibited a 20% incidence of Grade 3 or worse adverse events compared to 45% in the continuous group. These results support further Phase 2 and Phase 3 studies for zandelisib in patients with B-cell malignancies.

MEI Pharma, Inc. (NASDAQ: MEIP) announced a grant of inducement stock options totaling 65,000 shares to two new employees, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.60 per share, equivalent to the closing price on the grant date. These options are part of the 2021 Inducement Grant Equity Compensation Plan and will vest over a 10-year term. MEI Pharma focuses on developing new cancer therapies, notably zandelisib, currently undergoing clinical trials aimed at marketing approval from regulatory authorities.